×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Incathlab member and receive full access to its content!

You must be an Incathlab member to access videos without any restrictions. Register for free in one minute and access all services provided by Incathlab.You will also be able to log into Incathlab from your Facebook or twitter account by clicking on login on the top-right corner of Incathlab website.

Registration Login


Worldwide schedules comment Share

Découvrez comment le nouveau système d’imagerie endocoronaire Ultreon™ 1.0 Software, peut vous aider à optimiser votre procédure d’angioplastie. Apprenez étape par étape comment utiliser l’OCT pour préparer une lésion longue et calcifiée et optimiser le stenting.

Agenda:

  Présentation des objectifs de la session et présentation du Cas
 
  Live-in-a box case partie I 
 
  Présentation de l’algorithme MLD et de l’algorithme Ca2+
 
  Live-in-a-box case partie II
 
  Introduction à l’athérectomie Orbitaire
 
  Live-in-a box case partie III
 
  Discussion et présentation de l’algorithme MAX
 
  Questions-réponses
 
  Conclusion
 

 

Objectifs:

  • Comprendre le rôle de l’imagerie endovasculaire dans la prise en charge des lésions longues et calcifiées
  • Comprendre l’algorithme MLD MAX pour la stratégie et l’optimisation de l’angioplastie
    • Optimiser la préparation d’une lésion longue et calcifiée à l’aide de l’OCT sans impact sur le temps de procédure.
    • Adapter la stratégie de l’angioplastie grâce à l’OCT.
    • Optimiser le résultat de l’angioplastie grâce à l’OCT.
  • Session de questions/réponses “Live” avec les opérateurs.

 

Shooting date : 2022-07-04
Last update : 2022-07-07

Suggestions

Discover it now!

Nothing is simple

Alex & The Young Generation - Ep.9

Share
Wednesday, May 22nd 2024 from 03pm to 04pm (GMT+2)
Honolulu : Wednesday, May 22nd 2024 from 03am to 04am (GMT+2)
San Francisco : Wednesday, May 22nd 2024 from 06am to 07am (GMT+2)
New York : Wednesday, May 22nd 2024 from 09am to 10am (GMT+2)
Buenos Aires : Wednesday, May 22nd 2024 from 10am to 11am (GMT+2)
Reykjavik : Wednesday, May 22nd 2024 from 01pm to 02pm (GMT+2)
London / Dublin : Wednesday, May 22nd 2024 from 02pm to 03pm (GMT+2)
Paris / Berlin : Wednesday, May 22nd 2024 from 03pm to 04pm (GMT+2)
Istanbul : Wednesday, May 22nd 2024 from 04pm to 05pm (GMT+2)
Moscou / Dubaï : Wednesday, May 22nd 2024 from 05pm to 06pm (GMT+2)
Bangkok : Wednesday, May 22nd 2024 from 08pm to 09pm (GMT+2)
Shanghai : Wednesday, May 22nd 2024 from 09pm to 10pm (GMT+2)
Tokyo : Wednesday, May 22nd 2024 from 10pm to 11pm (GMT+2)
Sydney : Thursday, May 23rd 2024 from 12am to 01am (GMT+2)
Wellington : Thursday, May 23rd 2024 from 02am to 03am (GMT+2)

DanGER shock trial results and the significance to reduce adverse events

Share
Wednesday, April 2nd 2025 from 06pm to 07pm (GMT+2)
Honolulu : Wednesday, April 2nd 2025 from 06am to 07am (GMT+2)
San Francisco : Wednesday, April 2nd 2025 from 09am to 10am (GMT+2)
New York : Wednesday, April 2nd 2025 from 12pm to 01pm (GMT+2)
Buenos Aires : Wednesday, April 2nd 2025 from 01pm to 02pm (GMT+2)
Reykjavik : Wednesday, April 2nd 2025 from 04pm to 05pm (GMT+2)
London / Dublin : Wednesday, April 2nd 2025 from 05pm to 06pm (GMT+2)
Paris / Berlin : Wednesday, April 2nd 2025 from 06pm to 07pm (GMT+2)
Istanbul : Wednesday, April 2nd 2025 from 07pm to 08pm (GMT+2)
Moscou / Dubaï : Wednesday, April 2nd 2025 from 08pm to 09pm (GMT+2)
Bangkok : Wednesday, April 2nd 2025 from 11pm to 12am (GMT+2)
Shanghai : Thursday, April 3rd 2025 from 12am to 01am (GMT+2)
Tokyo : Thursday, April 3rd 2025 from 01am to 02am (GMT+2)
Sydney : Thursday, April 3rd 2025 from 03am to 04am (GMT+2)
Wellington : Thursday, April 3rd 2025 from 05am to 06am (GMT+2)

Le choix des armes contre les lésions calcifiées

Nouveaux outils pour la prise en charge de calcifications coronaires

Share
Saturday, November 8th 2025 from 01:30pm to 02:15pm (GMT+1)
Honolulu : Saturday, November 8th 2025 from 01:30am to 02:15am (GMT+1)
San Francisco : Saturday, November 8th 2025 from 03:30am to 04:15am (GMT+1)
New York : Saturday, November 8th 2025 from 06:30am to 07:15am (GMT+1)
Buenos Aires : Saturday, November 8th 2025 from 08:30am to 09:15am (GMT+1)
London / Dublin : Saturday, November 8th 2025 from 11:30am to 12:15pm (GMT+1)
Paris / Berlin : Saturday, November 8th 2025 from 12:30pm to 01:15pm (GMT+1)
Istanbul : Saturday, November 8th 2025 from 01:30pm to 02:15pm (GMT+1)
Moscou / Dubaï : Saturday, November 8th 2025 from 03:30pm to 04:15pm (GMT+1)
Bangkok : Saturday, November 8th 2025 from 06:30pm to 07:15pm (GMT+1)
Shanghai : Saturday, November 8th 2025 from 07:30pm to 08:15pm (GMT+1)
Tokyo : Saturday, November 8th 2025 from 08:30pm to 09:15pm (GMT+1)
Sydney : Saturday, November 8th 2025 from 09:30pm to 10:15pm (GMT+1)
Wellington : Saturday, November 8th 2025 from 11:30pm to 12:15am (GMT+1)

SELUTION DeNovo 1-year data – New data = New perspectives?

What do the SELUTION DeNovo 1-year results mean for clinical practice in Germany?

Share
Monday, October 30th 2023 from 05pm to 06pm (GMT+1)
Honolulu : Monday, October 30th 2023 from 05am to 06am (GMT+1)
San Francisco : Monday, October 30th 2023 from 07am to 08am (GMT+1)
New York : Monday, October 30th 2023 from 10am to 11am (GMT+1)
Buenos Aires : Monday, October 30th 2023 from 12pm to 01pm (GMT+1)
London / Dublin : Monday, October 30th 2023 from 03pm to 04pm (GMT+1)
Paris / Berlin : Monday, October 30th 2023 from 04pm to 05pm (GMT+1)
Istanbul : Monday, October 30th 2023 from 05pm to 06pm (GMT+1)
Moscou / Dubaï : Monday, October 30th 2023 from 07pm to 08pm (GMT+1)
Bangkok : Monday, October 30th 2023 from 10pm to 11pm (GMT+1)
Shanghai : Monday, October 30th 2023 from 11pm to 12am (GMT+1)
Tokyo : Tuesday, October 31st 2023 from 12am to 01am (GMT+1)
Sydney : Tuesday, October 31st 2023 from 01am to 02am (GMT+1)
Wellington : Tuesday, October 31st 2023 from 03am to 04am (GMT+1)

How do the new antithrombotic recommendations affect your HBR patients?

Gain insights from a patient case analysis

Share
Scroll Up